Adelman; Burt

Patent Applications and Registrations

Patent applications and USPTO patent grants for Adelman; Burt.The latest application filed is for "assays for determining plasma kallikrein system biomarkers".

Company Profile

4.9.18

Adelman; Burt - Concord MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Assays For Determining Plasma Kallikrein System Biomarkers App 20220291232 - Sexton; Daniel J. ; et al.	2022-09-15
Bispecific antibodies against plasma kallikrein and Factor XII Grant 11,390,687 - Comeau , et al. July 19, 2	2022-07-19
Assays for determining plasma kallikrein system biomarkers Grant 11,372,002 - Sexton , et al. June 28, 2	2022-06-28
Plasma Kallikrein Inhibitors And Uses Thereof For Preventing Hereditary Angioedema Attack App 20220169749 - Chyung; Yung ; et al.	2022-06-02
Evaluation And Treatment Of Bradykinin-mediated Disorders App 20220170936 - Sexton; Daniel J. ; et al.	2022-06-02
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack Grant 11,286,307 - Adelman , et al. March 29, 2	2022-03-29
Methods of determining levels of cleaved and/or intact kininogen Grant 11,156,612 - Sexton , et al. October 26, 2	2021-10-26
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema Grant 11,084,884 - Sexton , et al. August 10, 2	2021-08-10
Monoclonal Antibody Inhibitor Of Factor Xiia App 20210230299 - Mason; Shauna ; et al.	2021-07-29
Plasma Kallikrein Binding Proteins And Uses Thereof In Treating Hereditary Angioedema App 20210087293 - Sexton; Daniel J. ; et al.	2021-03-25
Monoclonal antibody inhibitor of factor XIIA Grant 10,913,802 - Mason , et al. February 9, 2	2021-02-09
Diagnosis And Treatment Of Autoimmune Diseases App 20200371120 - Sexton; Daniel J. ; et al.	2020-11-26
Diagnosis and treatment of autoimmune diseases Grant 10,648,990 - Sexton , et al.	2020-05-12
Diagnosis And Treatment Of Autoimmune Diseases App 20190120862 - Sexton; Daniel J. ; et al.	2019-04-25
A Monoclonal Antibody Inhibitor Of Factor Xiia App 20190002584 - Mason; Shauna ; et al.	2019-01-03
Plasma Kallikrein Inhibitors And Uses Thereof For Treating Hereditary Angioedema Attack App 20180362664 - Adelman; Burt ; et al.	2018-12-20
Plasma Kallikrein Inhibitors And Uses Thereof For Preventing Hereditary Angioedema Attack App 20180298110 - Chyung; Yung ; et al.	2018-10-18
Diagnosis and treatment of autoimmune diseases Grant 10,101,344 - Sexton , et al. October 16, 2	2018-10-16
Bispecific Antibodies Against Plasma Kallikrein And Factor Xii App 20180118851 - Comeau; Stephen R. ; et al.	2018-05-03
Plasma Kallikrein Binding Proteins And Uses Thereof In Treating Hereditary Angioedema App 20170002094 - Sexton; Daniel J. ; et al.	2017-01-05
Diagnosis And Treatment Of Autoimmune Diseases App 20160252533 - Sexton; Daniel J. ; et al.	2016-09-01
Assays For Determining Plasma Kallikrein System Biomarkers App 20160252527 - Sexton; Daniel J. ; et al.	2016-09-01
Evaluation And Treatment Of Bradykinin-mediated Disorders App 20150362493 - Sexton; Daniel J. ; et al.	2015-12-17
Methods of treating viral disorders Grant 7,662,921 - Adelman , et al. February 16, 2	2010-02-16
Methods of Treating Viral Disorders App 20080019960 - Adelman; Burt ; et al.	2008-01-24
Use of a CD40:CD154 binding interruptor to treat immunological complications of the eye App 20030027744 - Dana, M. Reza ; et al.	2003-02-06
CD154 blockade therapy for therapeutic protein inhibitor syndrome App 20020119151 - Adelman, Burt	2002-08-29

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.